# BPC-157 TB-500 FAQ: Wolverine Blend Questions, Answered and Cited

> BPC-157 TB-500 FAQ: what the Wolverine blend is, whether the synergy is proven, mechanisms, dose context, half-life, side effects, the tumor signal, FDA 503A status, and WADA. Direct answers, cited.

Direct answers on the Wolverine blend — definition, mechanism, dose context, safety, and the regulatory record — each scanned to its source where it makes a quantitative claim.

## Definition and difference

These answers cover what the BPC-157 TB-500 blend is, what its constituents are, and how they differ. Each is a direct answer first, context second.

## Mechanism and combination

These answers cover how each peptide works and what the "synergy" of the combination does — and does not — rest on.

## Evidence and efficacy

These answers cover the tissue-specific findings and the human-data record, with the consistent flag that the evidence is single-compound and largely rodent.

## Dose, route, and handling

These answers cover the practical dosing and reconstitution questions, with the same flag throughout: no validated dose for the blend.

## Safety and the tumor signal

These answers cover the safety questions honestly: no controlled human safety data for the blend, and a real theoretical concern around Thymosin Beta-4.

## Regulatory and access

These answers summarize the regulatory record; the [Wolverine legal status and FDA 503A category](/legal-status) page covers it in full and cites FDA.

---

A verification terminal for the BPC-157 TB-500 blend — each constituent finding scanned against its own study, the combination link flagged UNVERIFIED, and the FDA 503A access record read before anything else; no clinic behind the console and nothing here dispensed.